The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22338019.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0409.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients' unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- CTLA-4 Antigen
- Melanoma